424 Rec'd PCT/PTO 26 MAY 2000

FORMPTO-1390(Modified) (REV 11-98) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371

ATTORNEY'S DOCKET NUMBER: 11692-004001

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR): 09/555350

INTERNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED
PCT/DE98/03543	27 November 1998	28 November 1997

TITLE OF INVENTION

CELL-SPECIFIC RETROVIRAL VECTORS WITH ANTIBODY DOMAINS AND METHOD FOR THE PRODUCTION THEREOF FOR SELECTIVE GENE TRANSFER

APPLICANT(S) FOR DO/EO/US

Klaus CICHUTEK; Martin ENGELSTADTER

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
   a. ☒ is transmitted herewith (required only if not transmitted by the International Bureau).
   b. ☐ has been transmitted by the International Bureau.
   c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☐ A copy of the International Search Report (PCT/ISA/210).
8. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
   a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
   b. ☐ have been transmitted by the International Bureau.
   c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
   d. ☒ have not been made and will not be made.
9. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
10. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
11. ☐ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).

Items 13 to 20 below concern document(s) or information included:

13. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☒ A **FIRST** preliminary amendment.
16. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
17. ☐ A substitute specification.
18. ☐ A change of power of attorney and/or address letter.
19. ☒ Certificate of Mailing by Express Mail
20. ☒ Other items or information: Translation of Sequence listing as amended on April 22, 1999

"Express Mail" label number: el266435374us
Date of Deposit : 26 May 2000
I hereby certify that under 37 CFR 1.10 that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office To Addressee" with sufficient postage on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Samantha Bell

Samantha Bell

PCTUS1/REV03

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR)	INTERNATIONAL APPLICATION NO.	ATTORNEY'S DOCKET NUMBER
	PCT/DE98/03543	11692-004001

21. The following fees are submitted:.

BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :		CALCULATIONS	PTO USE ONLY
☐ Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2) paid to USPTO and International Search Report not prepared by the EPO or JPO	$970.00		
☒ International preliminary examination fee (37 CFR 1.482) not paid to USPTO but Internation Search Report prepared by the EPO or JPO	$840.00		
☐ International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO	$690.00		
☐ International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4)	$670.00		
☐ International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4)	$96.00		
ENTER APPROPRIATE BASIC FEE AMOUNT =		$840.00	
Surcharge of **$130.00** for furnishing the oath or declaration later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).		$0.00	

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	18 - 20 =	0	x $18.00	$0.00	
Independent claims	1 - 3 =	0	x $78.00	$0.00	
Multiple Dependent Claims **(check if applicable)** .			☐	$0.00	
TOTAL OF ABOVE CALCULATIONS =				$840.00	
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28) **(check if applicable)** .			☐	$0.00	
SUBTOTAL =				$840.00	
Processing fee of **$130.00** for furnishing the English translation later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492 (f)). +				$0.00	
TOTAL NATIONAL FEE =				$840.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) **(check if applicable).**			☐	$0.00	
TOTAL FEES ENCLOSED =				$840.00	
				Amount to be: refunded	$
				charged	$

☒ A check in the amount of **$840.00** to cover the above fees is enclosed.

☐ Please charge my Deposit Account No. in the amount of to cover the above fees.
A duplicate copy of this sheet is enclosed.

☒ The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. **06-1050** A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

J. Peter Fasse
Fish & Richardson P.C.
225 Franklin Street
Boston, Massachusetts 02110-2804
United States of America

J. Peter Fasse
SIGNATURE

J. Peter Fasse
NAME

32.983
REGISTRATION NUMBER

26 May 2000
DATE

Attorney's Docket No.: 11692-004001 / 158-2US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Cichutek et al. Art Unit : Unknown
Serial No. : Examiner : Unknown
Filed : May 26, 2000
Title : CELL-SPECIFIC RETROVIRAL VECTORS WITH ANTIBODY DOMAINS AND METHOD FOR THE PRODUCTION THEREOF FOR SELECTIVE GENE TRANSFER

Commissioner of Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Prior to consideration on the merits, please amend the application as indicated below.

In the Specification (English translation):

At page 1, after the title, insert, centered

--Field of the Invention--.

At page 1, after line 6 of text, insert, centered

--Background of the Invention--.

At page 3, after line 20, insert, centered

--Summary of the Invention--.

At page 5, after line 2, insert

--Other features and advantages of the invention will be apparent from the following detailed description, and from the claims.

Brief Description of the Drawings--.

At page 5, after line 12, insert, centered

--Detailed Description--.

CERTIFICATE OF MAILING BY EXPRESS MAIL

Express Mail Label No. EL266435374US

I hereby certify under 37 CFR §1.10 that this correspondence is being deposited with the United States Postal Service as Express Mail Post Office to Addressee with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

26 May 26, 2000
Date of Deposit

Samantha Bell
Signature

Samantha Bell
Typed or Printed Name of Person Signing Certificate

At page 14, after line 2, insert

--Other Embodiments

It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.--.

In the Claims:

In claim 3, line 1, delete "or 2".

In claim 4, line 1, delete "any of the" and delete "to 3".

In claim 5, line 1, delete "any of the" and delete "to 4".

In claim 6, line 1, delete "any of the" and delete "to 4".

In claim 8, line 1, delete "any of the" and delete "to 7".

In claim 10, line 1, delete "any of the" and delete "to 9".

REMARKS

Applicants submit this Preliminary Amendment to conform this application to U.S. patent practice. The amendments to the specification insert standard subheadings and transitional paragraphs. The amendments to the claims delete multiple dependencies and improper claim formats. These amendments add no new matter.

Please note that applicants intend to file a second Preliminary Amendment to further revise the claims. Applicants request that the Examiner contact the undersigned by telephone in case the second Preliminary Amendment has not yet been entered by the time the Examiner wishes to begin examination.

No additional fees are believed due. However, please apply any credits or charges to Deposit Account No. 06-1050, referencing Attorney Docket No. 11692-004001.

Respectfully submitted,

Date: 26 May 2000

J. Peter Fasse
Reg. No. 32,983

Fish & Richardson P.C.
225 Franklin Street
Boston, MA 02110-2804
Telephone: (617) 542-5070
Facsimile: (617) 542-8906

20087853.doc

CELL-SPECIFIC RETROVIRAL VECTORS WITH ANTIBODY DOMAINS AND METHOD FOR THE PRODUCTION THEREOF FOR SELECTIVE GENE TRANSFER

The present invention relates to cell-specific retroviral vectors with antibody recognition domains (scFv) which are suitable for cell-specific transduction of a selected mammalian cell type (cell targeting), methods for the preparation of the cell-specific retroviral vectors and their use for the gene transfer into selected cells. The invention further relates to retroviral packaging cells to obtain the cell-specific retroviral vectors of the present invention.

The majority of retroviral vectors which are presently used in gene therapeutic research are derived from the amphotropic murine leukemia virus (MLV). The host cell range of the amphotropic MLV is determined by the surface envelope protein (SU) encoded by the env gene. The protein products of the env gene form the outer envelope of the retroviral vector. The SU proteins interact with, i.e. bind to a specific protein (receptor) on the surface of the host cell. The env gene products of the amphotropic MLV enable gene transfer into a great number of different mammalian cells. However, a selective gene transfer in particular cell or tissue types of humans or other mammals is not possible, since the receptor for the MLV envelope proteins on the surface of mammalian cells which mediates the entry of amphotropic MLV vectors and gene transfer, is found on nearly all of these cells. Accordingly, the host cell range of the amphotropic MLV is not specific.

A host cell specificity, however, is advantageous e.g. for gene therapeutic use, since in a gene therapy outside of the organism (ex vivo) (Anderson et al., Science 256 (1992) 808-813; Yu et al., H. Gene Therapy 8 (1997) 1065-1072) laborious purifications of cells are avoided. It is desired for therapeutic, diagnostic or vaccination use *in vivo*, that retroviral vectors are targeted specifically to the desired host cells and subsequently transfer the therapeutic gene. By modification of the surface envelope protein a restriction of the host cell range of the amphotropic MLV could be achieved. A modification of the surface capsid protein was done by fusion with a hormone domain. A transduction of the cells carrying the specific hormone receptor occurred (Kasahara et al., Science 266 (1994) 1373-1375). Further, the surface envelope protein was modified by fusion with a single chain antibody fragment (single chain variable fragment, in the following referred to as "scFv"). The fragment represented the antigen binding domain of an antibody and is a fusion protein composed of the variable domains Vh and Vl of a monoclonal antibody. Both domains are linked via a glycine and serine oligopeptide [-(ser-gly4)3-gly-)] which enables the correct folding of the fusion protein (Huston et al., Methods Enzymol. 203 (1991) 46-88, Whitlow et al., Methods: A companion to Methods Enzymol. 2 (1991) 97-105). All modifications of the MLV surface capsid protein using a scFv carried out so far showed that while binding of the

vectors to the host target cell occurred, however, there was no entry into the cell (Russel et al., Nucleic Acid Res. 21 (1993) 1081-1085). Furthermore it is known that the surface envelope protein of the MLV generally does not enable for extensive modifications (Cosset et al., J. Virol. 69 (1995) 6314-632). Modifications in which a portion of the binding domain of the MLV-SU protein has been replaced led to an incorrect processing and, thus, to a defective transport of the SU protein to the cell surface (Weiss et al., In J.A. Levy (ed.) The Retroviridae 2 (1993) 1-108; Morgan et al., J. Virol. 67 (1993) 4712-4721; Russel et al., Nucleic Acid Res. 21 (1993) 1081-1085). Accordingly, the development of cell-specific retroviral vectors on the basis of MLV with modified surface envelope proteins is only little promising.

Retroviral vectors on the basis of spleen necrosis virus SNV are more suitable for a targeted gene transfer into e.g. human cells, since the surface envelope protein of SNV enables for extensive modifications after which still correct processing occurs (Martinez and Dornburg, Virol. 208 (1995) 234-241; Chu et al., Gene Therapy 1 (1994) 292-299; Chu and Dornburg J. Virol. 69 (1995) 2659-2663). At least two components are required for the preparation of such vectors. On the one hand a so-called expression construct is to be prepared enabling packaging in and transfer through a retrovirus. The expression construct comprises a coding DNA fragment of the desired gene product, e.g. a gene for gene therapy or as a vaccine. The expression construct has to comprise a nucleotide sequence which is referred to as packaging signal psi (ψ) and controls the efficient packaging of mRNA in retroviral particles. Furthermore a packaging or helper cell is required which provides the gag, pol and env gene products of SNV, without packaging of the gag, pol and env genes into a retrovirus. The gag, pol and env genes which are present in the packaging cell have to be psi-negative. Following transduction of the expression construct by means of transfection of the respective plasmid DNA into the packaging cells, retroviral particles are released into the cell culture supernatant, which particles contain the expression construct and are only able to transduct said construct but not the gag, pol and env genes into the target cell. Said vectors are replication incompetent and only pass one cycle of replication. The general method for the preparation of replication incompetent retroviral vectors is known in the prior art (Weiss et al., In J.A. Levy (ed.). The Retroviridae 2 (1993) 1-108; Morgan et al., J. Virol. 67 (1993) 4712-4721; Russel et al., Nucleic Acid Res. 21 (1993) 1081-1085; Cosset et al., J. Virol 69 (1995); Martinez and Dornburg, Virol. 208 (1995) 234-241; Chu et al., Gene Therapy 1 (1994) 292-299; Chu and Dornburg, J. Virol. 69 (1995) 2659-2663).

The tropism (host cell specificity) of spleen necrosis virus is determined by the surface envelope protein (SU protein) encoded by the env gene of SNV. The wild type SNV surface envelope protein does not allow for a selective gene transfer into particular human cells or tissues since the specific acceptor protein (receptor) is not present on the surface of human cells (Dornburg, Gene Therapy 2 (1995) 1-10). Therefore, a method has been

developed to substitute the SU protein of SNV by the antigen recognizing domains of antibodies. Said [SNV-scFV-Env] vectors with the two different scFv known heretofore were able to transmit the psi positive reporter gene, bacterial β-galactosidase, into the selected human target cells. Said scFv are directed against the hapten dinitrophenol (DNP) or against an unknown surface molecule on colon CA cells and other cancer cells, respectively. (Chu et al., Gene Therapy 1 (1994) 292-299, Chu et al., BioTechniques 18 (1995) 890-899; Chu and Dornburg, J. Virol. 71 (1997) 720-725). A packaging cell line (DSH-CXL) has been developed, containing the psi-negative SNV genes gag, pol and env as well as the psi-positive reporter gene expression construct (pCXL). Following transfection of the packaging cell using plasmid DNA of another env expression gene (pTC53), in which the entire surface envelope protein was substituted by a single chain antibody fragment (scFv), retroviral vectors were released into the cell supernatant which in addition to the wild type surface envelope protein also carried the chimeric [scFv-Env] surface protein on their surface. By means of said vectors the reporter gene could be transferred into the target cells specific for scFv, canine osteosarcoma cells (D17), which were conjugated with DNP, or HeLA cells (human cervical carcinoma cells), respectively. However, this method described for the preparation of cell-specific retroviral vectors has the disadvantage that only already known and cloned scFv may be used. Further, it has been found by us that not every scFv is suitable as a portion of a [SNV-scFv-Env] vector for cell transduction (transfer of the desired gene to the target cell).

Generally, the gene transfer into mammalian cells by means of retroviruses has the following benefits:

- Normally, one copy of the desired gene is transferred into the mammalian cell.
- Generally, the desired gene is transferred without mutation or rearrangements.
- Stable introduction of the desired gene into the genome of the target cell occurs.

Furthermore, it is desired that the retroviral vector has a particular cell-specificity by which e.g. the therapeutic gene may be introduced into a selected cell population.

Therefore, it is an object of the present invention to provide cell-specific retroviral vectors having antibody recognition domains for selective gene transfer into mammalian cells as well as a universal method for the preparation thereof. It is possible to improve the gene transfer by means of said vectors. A further object of the invention is to provide retroviral packaging cells for obtaining the vectors according to the present invention. The solution of said objects is obvious from the claims, the following description and the figures.

The object is solved by the method of the present invention for the preparation of cell-specific retroviral vectors comprising the following steps of: a) Immunizing a mammal with one or more cell population(s), b) Isolation of RNA from the mammal immunized, comprising the B cell RNA, c) preparation of cDNA portions of the variable regions of the immunoglobulin heavy and light chains from the isolated RNA by means of RT-PCR using

primers for the immunoglobulin heavy and light chain wherein the primers comprise the nucleic acid sequence for an oligopeptide linker, d) ligation of the cDNA portions to scFv-cDNAs, e) ligation of the scFv-cDNAs into a phagemid vector and transformation of a host bacterium with said phagemid vector, f) isolation of phages which bind to the cell population(s) used in step a) by means of selection, g) isolation of cell-specific phages from the phages obtained in step f) which only bind to the cell population(s) used in step a) by means of selection, h) excising the scFv encoding DNA fragments from the cell-specific phages obtained in step g) and ligation into a psi-negative retroviral Env expression vector, i) transformation of the resulting Env-scFv expression vector into a packaging cell, and j) isolation of retroviral vectors secreted from the packaging cell.

Optionally, the method according to the present invention comprises further isolation of cell-specific phages obtained in step g). Optionally, the method of the invention further comprises the step: k) isolation of retroviral vectors secreted by the packaging cell, which transduce the cells of the cell population(s) by means of selection. Furthermore, the steps f) and/or g) may be repeated at least once.

A method is preferred in which the immunized mammal is selected from the group consisting of mouse, rat, guinea pig, rabbit, goat or sheep. Also preferred is a method in which the cell population(s) is/are selected from the group consisting of man, mouse, rat, sheep, cattle or pig. Particularly preferred is a method, in which the cell population(s) is/are selected from the group consisting of T cells, epithelial cells, muscle cells, stem cells, neural cells, hematopoietic cells, carcinoma cells or liver cells. A method is preferred in which the env gene is derived from spleen necrosis virus (SNV). Particularly preferred is a method in which the expression vector is the vector with the designation pTC53.

The cell-specific retroviral vectors obtainable by means of the method of the invention may be used as medicaments. Preferred is the use for the preparation of a medicament for gene therapy, vaccination therapy or diagnostics. Particularly preferred is the therapy of cystic fibrosis, ADA deficiency, HIV infections, leukemia, chronic granulomatosis.

Furthermore, the invention is solved by the provision of retroviral packaging cells for obtaining retroviral vectors of the invention, transformed both with one or more psi-negative expression construct(s) expressing gag, pol and/or env gene products and with a psi-negative Env-scFv expression construct according to claim 1h). A packaging cell is preferred further comprising a psi-positive expression construct, comprising a nucleic acid fragment, which is to be introduced into the cell to be transduced by the retroviral vector. Particularly preferred is a packaging cell wherein the nucleic acid fragment comprises a therapeutic gene or its DNA fragment and/or a reporter gene. Particularly preferred is a packaging cell wherein the therapeutic gene or its nucleic acid fragment comprises CFTR, phox91, ADA, IL-16, p53 or revM10 gene or vaccination genes, e.g. recombinant gp120 and IL-16. Further particularly

preferred is a packaging cell wherein the reporter gene comprises β-galactosidase, green fluorescent protein, luciferase or neomycin.

The figures are meant to illustrate the invention.

Fig. 1 schematically shows the ENV-scFv expression construct pTC53, pT-scFv and pT/zeo, the transfection thereof into the packaging cell DSH-CXL which secretes the vectors of the present invention.

Fig. 2 schematically shows the preparation, isolation and selection of the vectors of the invention.

Fig. 3 is a schematic illustration of an immunoglobulin and the scFv resulting therefrom. Furthermore, scFv display phages and SNV-scFv-Env vectors are schematically depicted.

Fig. 4 shows the nucleic acid sequence of pTC53.

The term amphotropic virus used herein means infection and replication in murine and human cells, in contrast to an ecotropic virus which only replicates in murine cells. The term retroviral vector used herein means replication deficient retroviral virus particle which instead of retroviral mRNA may transmit a foreign introduced RNA of a gene, e.g. of a therapeutic gene or a fragment thereof or of a reporter gene. The term antibody recognition domain (scFv) used herein means an antigen binding site of an antibody comprising Vh and Vl chain. The term SNV used herein represents spleen necrosis virus with its strains and substrains. SNV belongs to the avian reticolo endotheliosis viruses (REV), type D retrovirus.

To provide the cell-specific antibody recognition domains (scFv) a new combinatory phage cDNA library of the variable domains of the light and heavy chains of the immunoglobulins is prepared. For this purpose, a mammal, e.g. a mouse, rat, rabbit, guinea pig, goat or sheep is immunized with a sufficient titer of one or more cell population(s) in a usual manner. The cell population is the cell type forming a surface receptor to which the retroviral vectors of the present invention specifically bind. The cells may be derived from a mammal which is different from the mammal to be immunized, e.g. from human, mouse, rat, sheep, cattle or pig. The cells may be such cells in which for example a somatic gene therapy, a vaccination therapy or diagnostics is to be carried out. Typical examples of such cells are T-cells, liver cells, muscle cells, neural cells, fibroblasts, epithelial cells, stem cells or hematopoietic cells. For immunization one or more cell population(s) may be simultaneously administered to the mammal depending on the cell population(s) for which the retroviral vector of the present invention has to be specific.

For the preparation of a cDNA library B cell RNA of the immunized mammal is first isolated in a known manner. The mRNA sequences of the regions of the heavy and light chain (V_H and V_L) of the immunoglobulins responsible for antigen recognition, are transcribed into cDNA and amplified in a usual manner by means of reverse transcription

and subsequent polymerase chain amplification. The primer pairs and their sequences for V_H and V_L regions are known to the person skilled in the art. For example, they are contained in the kit commercially available from Pharmacia company, or may be obtained from known data bases (EMBL), respectively. It is known to the skilled artisan that he has to use different primer sequences for every immunized mammalian species. The sequences are also contained in the known data bases. The cDNA fragments of the V_H and V_L regions are then linked to scFv-cDNAs by means of a ligase reaction in a usual manner. It is obvious to the skilled artisan that during ligation different combinations of cDNA fragments are prepared. The resulting scFv-cDNAs may then be cloned into a phagemid vector, e.g. pCANTA 5E phagemid, Pharmacia company. Subsequently, host bacteria, e.g. E. coli TG1 are transformed with the phagemid vector.

The recombinant phages produced by the bacteria are then isolated in a usual manner and selected for the presence of cell-specific scFv peptides. The phages are then contacted in a usual manner with the cell population(s) which have been used for immunization. Phages not binding to cells do not carry a specific scFv peptide and are removed by means of washing steps in a usual manner. Phages binding to the cells present the desired scFv peptide on their surface and are eluted in a usual manner. Phages presenting the desired scFv peptide are amplified by allowing them to infect host bacteria in a usual manner. This selection step may be repeated once or several times to enrich the binding phages. This procedure is referred to as panning. The phages are subjected to a further selection after panning or directly after the first selection step. For this purpose the phages are contacted with one or more other cell population(s) which are different from the cells used for immunization. Phages not binding to said cells present a cell-specific scFv peptide. They are isolated from the cell supernatant in a usual manner and are used for a host bacteria infection for amplification. Also this selection step may be repeated once or several times (Marks et al., BioTechnology 10 (1992) 779; Clackson et al., Nature 352 (1991) 624; Marks et al., J. Mol. Biol. 222 (1991) 581; Chaudhary et al., Proc. Natl. Acad. Sci USA 87 (1990) 1066; Chiswell et al., TIBTECH 10 (1992) 80; McCafferty et al., Nature 348 (1990) 552; Huston et al., Proc. Natl. Acad. Sci. USA 85 (1988) 5879).

For the preparation of the cell-specific retroviral vectors of the present invention the above described phage cDNA library is used as a starting material. The scFv-cDNAs of the phages remaining after the second selection step and the panning method which has optionally been carried out are excised in a usual manner from the phage DNA and inserted into a retroviral Env expression gene. The retroviral env expression gene may be derived from SNV. A typical example for a SNV-scFv-env expression construct is pTC53. The sequence is shown in Figure 4B. A typical example for a wild type (wt) SNV-env expression construct is pIM29.

The construction of the expression plasmids encoding wt-SNV-ENV proteins, e.g. pIM29 and the chimeric SNV-scFv-ENV proteins has been previously described by Chu et al. (J. Virol. 71 (1997) 720-725). The expression of the DNA coding for the wt-env gene is controlled by an MLV promoter. The env-cDNA was excised from a plasmid encoding the complete SNV virus via restriction sites SacII and AvrII and introduced by insertion into a linker (L). To enable a correct processing of the protein pIM29 contains the polyadenylation site of Simian Virus 40 (SV 40). Thus, from this plasmid the expression of the wt-env gene may occur, so that following proteolytic cleavage of a precursor protein the outer glycoprotein (SU) and the transmembrane protein (TM) are obtained. However, other plasmids, promoters, linkers, polyadenylation signals known to the skilled artisan and further DNA elements required for a correct processing may be used.

For the expression of SNV-scFv-ENV proteins scFv obtained in a known manner are introduced into a SNV-ENV expression construct, e.g. pTC53, in a usual manner. The restriction recognition sites for the enzymes SfiI and NotI present in pTC53 enable the molecular cloning of e.g. scFv between the SNV-env- leader sequence and the DNA region encoding the transmembrane protein (TM protein). The protease cleavage site between SU and TM present in wt-ENV is deleted in pTC53, so that a fusion protein is expressed which consists of a single chain antibody fragment at the N-terminus and of the SNV-TM at the C-terminus. The regulatory elements, such as MLV promoter and SV40 polyadenylation signal are identical to those of the pIM29 vector. For enhancing the expression of a chimeric env gene an adenoviral leader sequence, e.g. Avtl (Sheay et al., BioTechiques 15 (1993) 856-861) is inserted into the expression plasmid pTC53. A zoezin cassette (pSV2zeo; Invitrogen Comp., The Netherlands) functions to select stably transfected cells, so that single cell clones may be established.

The psi-negative SNV-scFv-env expression construct may be introduced into packaging cells by means of electroporation or other known methods. A typical packaging cell is for example DSH-CXL. Further, packaging cells have psi-negative env, gag, pol expression constructs and for the desired gene transfer into the specific target cells a further psi-positive expression construct comprising for example a gene or DNA fragment for gene therapy, vaccination therapy or a reporter gene for diagnostics. Following transfection of the packaging cells a transient expression and release of retroviral vectors which present in addition to natural SU proteins recombinant SU-scFv proteins into the cell culture supernatant occurs. The retroviral vectors may then be used for transduction of the target cell, i.e. the cell population used for immunization in a usual manner. Optionally, said step may be a further selection step. Only the retroviral vectors of the invention which transduce the target cell in a sufficient manner are further employed. These vectors may be subjected to a further selection step. The vectors may be used in a conventional manner for transduction of cell populations different from the cell population used for immunizing said mammal.

Thus, vectors not transducing the other cells but only the target cells may be obtained in a double selection step.

For establishing of stable packaging cell lines which constitutively release the retroviral vectors of the invention, a selection marker, e.g. the zeocin resistance gene (Invitrogen), may be inserted in a usual manner into the scFv expression construct, e.g. pTC53. The scFv expression constructs provided with the zeocin resistance gene are transferred into the packaging cells e.g. by means of the liposome technique (lipofectamine, Gibco BRL). After a selection of about two weeks of the transfectants in zeocin containing culture medium cell clones may be established which transduced target cell populations with a titre of about 10^4-10^6 retroviral vectors pro ml depending on the scFv-cDNA fragment.

The gene transduced with the retroviral vectors of the invention into the target cell population or populations may for example be the RNA of a therapeutic gene or a fragment thereof. Therapeutic genes may for example be the CFTR gene, ADA gene, LDL receptor, β-globin, factor VIII or factor IX, dystrophin gene. The target cells in the case of the CFTR gene would be e.g. lung epithelial cells, in the case of the ADA gene the stem cells of bone marrow or T lymphocytes, for LDL receptor the liver cells, for dystrophin gene skeletal muscle cells, for β-globin gene hematopoietic stem cells, for factor VIII or factor IX fibroblasts and liver cells. It is obvious to the skilled artisan that this listing represents only a selection of therapeutic genes and other genes may also be used for a gene therapy. The DNA fragments of a therapeutic gene comprise for example antisense nucleic acids or ribozymes. Further, DNA fragments may comprise portions of a gene containing the trinucleotide repeats of e.g. the fragile X gene.

Further, the RNA of a reporter gene, e.g. β-galactosidase, GFP, luciferase or neomycin, may be introduced into the retroviral vectors of the present invention. The reporter genes enable the determination whether the target cells have been transduced with the retroviral vectors.

Further, the RNA of a gene or a fragment thereof may be transduced into the target cell for vaccination purposes. A typical vaccination gene is for example the recombinant gp120 or gp160 of HIV. The transduction of immune cells with these genes or fragments stimulates the antibody formation against viral gene products.

The vectors of the present invention may for example be applied by i.v. or i.m. injections. The packaging cells of the present invention may however be enclosed into e.g. organoids (Teflon bags), which are then implanted into the organism and secrete the vectors according to the present invention into the blood stream or tissue. Further application forms are obvious to the person skilled in the art.

The retroviral packaging cell of the invention for obtaining the pseudotyped retroviral vectors of the present invention is provided by transfecting a cell line e.g. a human cell line with psi-negative expression construct expressing the gag and pol gene products of SNV and

with the psi-negative SNV-Env expression construct and/or psi-negative SNV-scFv-env expression construct in a conventional manner.

Furthermore, packaging cells may be used, which already contain the psi-negative expression constructs for gag and pol gene products. Into such packaging cells only the psi-negative expression construct for the virus envelope and the psi-positive expression construct for the nucleic acid sequence to be transduced into the target cell have to be transfected. Methods for transfection of the expression constructs are known to the skilled artisan. By the packaging cells of the invention, retroviral vector particles are released into the cell supernatant which contain the expression construct, but not the constructs encoding GAG, POL and ENV proteins. Thus, only the desired e.g. therapeutic gene or reporter gene is transferred into the target cell.

The illustrated invention opens up following possibilities:

- Genes, gene fragments or other nucleic acid sequences may be transferred into selected mammalian cells.
- further enhancement of the efficiency of the nucleic acid transfer may be achieved by improvement of the env gene constructs.
-gene therapy, labeling and vaccination strategies may be developed, for which a selective nucleic acid transfer into selected mammalian cells is desirable.

The following examples illustrate the invention and are not intended to be limiting:

1. Isolation and cloning of cell-specific scFv

For the preparation, isolation and selection of cell-specific scFv a mouse was immunized with the human T cell line T-C8166 (Clapham et al., Virology 158 (1987) 44-51) in a conventional manner, the spleen removed and RNA was isolated. Cloning of the scFv-cDNAs was carried out with the commercially available kit of Pharmacia company according to the manufacturer's instructions. The resulting phages were examined in a conventional manner with respect to their binding characteristics to target cells. There were isolated 150 phages which specifically bound to the target cells. The 150 thus obtained cell-specific scFv were used to prepare the SNV-scFv vectors according to the present invention.

2. Cloning of specific scFv-cDNA fragments into Env expression constructs

The scFv-cDNAs of 150 cell-specific scFv were excised in a usual manner from the phagemid DNA and each of the DNAs was ligated into the expression construct pTC53. pTC53 was obtained by modification of the universal eukaryotic vector pRD114 (Chu et al., J. Virol. 71 (1997) 720-725; Sheay et al. BioTechniques 15 (1993) 856-861; Chu et al., BioTechniques 18 (1995) 890 - 895). In this vector the SNV-wt-env gene was deleted except for the leader sequence and the transmembrane-protein encoding cDNA. An additionally

inserted spacer enables the insertion of a foreign DNA (here scFv-cDNA) following the ENV-leader sequence via the restriction recognition site NaeI. The sequence of pTC53 is shown in figure 4. For the insertion of the scFv-cDNA the Env-expression construct pTC53 was modified so that Sfi I and Not I specific restriction endonuclease recognition sites are inserted between the SNV-leader sequence and SNV-transmembrane sequence (TM) in a usual manner. For this purpose a recombinant PCR is carried out in a usual manner starting from the DNA of the plasmid PKA1558 (Scov. H. & Andersen, K.B., 1993) and the DNA coding for the anti-transferrin receptor scFv so that via Nru I (5' and 3') an insertion of the amplified fragment into the Nae I restricted pTC53 is possible. The thus inserted fragment contains the multiple Sfi I/Not I cloning site since the primers used further include a neighboring Sfi I or Not I recognition site, respectively, in addition to the terminal Nru I recognition site. For recombinant PCR following primers were used:

PKATFNNRu+:

5'-GGGCCCTCGCGAGC*GGCCCAGCCGGCC*GACATCAAGATGACCCAGTCTCCA-3'

Nru I Sfi I

PKATFNRNRu-:

5'-GGGCCCTCGCGAT*GCGGCCGC*TGAGGAGACTGTGAGAGTGGTGCC-3'

Nru I Not I

The PCR conditions were: 94°C/3 min, 94°C/1 min, 59°C/1 min, 72°C/1 min., 25 cycles, 72°C/10 min and then cooling to 4°C. The PCR fragment was gel-electrophorized, extracted from the gel matrix (Quiaex, Quiagen Comp.) and ligated in a conventional manner with the plasmid pTC53 opened with Nae I.

The scFv-cDNAs from the phagemid (pCANTA 5E) were excised by means of the restriction endonucleases Sfi I and Not I. For this purpose the phagemid-plasmid DNA was prepared by means of known methods, and in each case 8 µg of plasmid DNA were digested with 60 U each of the restriction endonucleases Sfi I and Not I at 50°C for 1.5 h and subsequently at 37°C for 1.5h. The reaction batch occurred in a volume of 200 µl which was supplemented with 20 µl BSA (10 x conc.) and 20 µl reaction puffer 3 (10 x conc.). Upon completion of the reaction period the batch was electrophorized on a 1% agarose gel. Following separation the scFv-cDNA specific band (about 750 bp) was purified from the agarose gel by means of known methods.

The purified fragment was ligated with the Env expression construct pTC53 which has also been opened with the restriction endonucleases Sfi I and Not I. For this purpose

equimolar amounts of the scFv-cDNA fragment and pTC53 fragment were supplemented with 200 U T4 ligase and 1.5 µl 10x ligase buffer in a 15 µl volume. The batch was incubated at 4°C over night. To enable an efficient transformation of bacteria the bacterial strains TOP10F' and JS5 were made competent by means of a modified method according to Hanahan (1983). Following inoculation of 100 ml LB-medium with 500 µl of an overnight culture, the bacterial suspension was incubated at 37°C up to a density (OD_{550}) of 0.6. Subsequently, the bacteria were chilled on ice, pelleted at 6000 rpm and 4°C (Minifuge RF, Heraeus, Hanau) and resuspended in 40 ml TFB1 buffer (30 mM KOAc, 100 mM $RbCl_2$, 10 mM $CaCl_2$, 15% glycerol, pH 5.8, adjusted with acetic acid, thereafter filter sterilized). After an incubation period of 15 min on ice and centrifugation at 6000 rpm and 4°C the bacterial pellet was resuspended in 4 ml of TFB2 buffer (10 mM MOPS, 75 mM $CaCl_2$, 10 mM $RbCl_2$, 15% glycerol, pH-Wert 6.5, adjusted with KOH solution, thereafter filter sterilized). The bacterial suspension was then divided into aliquots of 100 µl each and then shock frozen on dry ice. The storage was carried out at -70°C. For transformation, 100 µl of competent bacteria were thawed on ice and following addition of 1-2 µl of the respective ligation batch incubated on ice for 30 min. After a subsequent temperature shock (45 s at 42°C, thereafter 2 min on ice) the bacteria were added with 500 µl SOC medium (GIBCO/BRL, Eggenstein) and cultivated for 1 h at 37°C for expression of antibiotic resistance in a bacterial shaker. The bacterial suspension was streaked out on LB agar plates supplemented with the antibiotic ampicillin and incubated at 37°C over night.

The preparation of plasmids from bacteria (E. coli TopF10) was done with the QIAGEN plasmid kits of QIAGEN company, Hilden. For the preparation of a low amount of plasmid DNA the bacteria of a 15 ml overnight culture (LB medium with 50 µg/ml ampicillin) were lysed with the solutions provided by the manufacturer and purified via an anion exchange column (tip 20). For the preparation of large amounts of plasmid DNA (maxi preparation) 400 ml overnight cultures were prepared.

3. Selection of retroviral vectors

Transient transfection of the scFv-pTC53 expression constructs into the packaging cell DSH-CXL by means of electroporation: for each electroporation 2 x 10^6 DSH-CXL cells were resuspended in 480 µl PBS and added to a Gene-Pulser cuvette (0.4 cm electrode, gap 50, Biorad, Munich). Thereafter 20 µg of recombinant plasmid DNA were added to the cell solution. The content of the cuvette was subjected to an electric pulse in an electroporator (Gene-Pulser Apparatus, Biorad, Munich) at 270 V and 960 µF. After 10 min of incubation of the cuvette on ice the cells were added into 20 ml of fresh culture medium in a medium sized cell culture flask (Nunc, Wiesbaden). The next day the DSH-CXL cells were added with fresh medium and cultivated.

The virus containing supernatant of the transfectants was used for transduction of the target cells. The day before transduction the C8166 target cells were transferred to fresh medium in a ratio of 1:2. The supernatants were filter sterilized with a 0.45 µm filter (Sartorius). 7 ml of the supernatant were directly employed for transduction of 2 x 10^5 C8166 cells. To stabilize the junction of the retroviral vectors to the cell surface, 40 µg/ml Polybrene were added. Following 2 h of incubation at 37°C the cells were washed with PBS and transferred into fresh culture medium.

Detection of β-galactosidase activity (X-Gal assay): For examination of a successful transduction an X-Gal assay was carried out after 72 hours according to a modified method of Sanes et al. (1986). The cell culture supernatant was removed and the cells washed with PBS without (Ca^{2+} and Mg^{2+}). Subsequently, the cells were overlaid with a fixation solution (2% formaldehyde, 0.2% glutaraldehyde in PBS) for 5 min and washed with PBS. Thereafter, the cells were resuspended in 3 ml of X-Gal reaction mix solution (1 mg/ml, 5 mM K-Ferricyanide, 5 mM K-Ferrocyanide, 2 mM $MgCl_2$). After an approx. 4 h period of incubation of the batch at 37° blue staining of the transduced cells occurred.

6 of the 150 tested scFv-pTC53 expression constructs were cell-specific (M8, K6, 7A5, 7E10, 6C3, 7B4). That means, that per cell-specific construct 10-20 blue-stained C8166 cells could be recognized. Compared to non-cell specific scFv-clones, this result is significant. Stable packaging cell lines were generated from 6 cell-specific scFv expression constructs.

4. Establishment of stable packaging cell lines.

Preparation of zeocin resistance gene by means of PCR starting from DNA of the plasmid pSCV Zeo (Invitrogen Comp.): To select packaging cells after a stable transfection with the pTC53-zeo-scFv plasmid for a stable expression of the resistance gene, a zeocin cassette was integrated. For this purpose, a zeocin cassette was amplified by means of recombinant PCR from the vector pZeoSV2 (+/-) of Invitrogen Company (NV Leek, The Netherlands) and provided with the restriction sites NdeI 5' and 3' so that the cassette subsequently could be inserted into the NdeI restricted portion of the pUC19 backbone of pTC53. The PCR-batch (100 µl) contained: 1 x PCR buffer (Taq: 10 mM Tris/HCl, pH 8.8, 50 mM KCl, 1.5 mM $MgCl_2$, 0.01% gelatin, 10 µM (+)- and 10 µM (-)-primer, 200 µM of each deoxynucleotide, 2.5 units of Taq polymerase and 100 ng of plasmid DNA. Following oligonucleotides have been used:

ZEO2184+NDE:

5'-GGAAATTCCATATGGAATTCCCGTTACATAACTTACGGTAAATGGC-3'

Nde I

ZEO3258-NDE:

5'-GGAATTCCATATGGAATTCCTCAGTCCTGCTCCTCGGCC-3'

Nde I

The PCR-conditions were: 94°C/3 min, [94°C/1 min, 60°C/1 min, 72°C/1,5 min.] 30 cycles, 72°C/10 min and 4°C final temperature.

Insertion of a zeocin resistance gene into the scFv pTC53 Env expression constructs positive in the transient test.

Transfection by means of Lipofectamin™ (GIBCO/BRL, Life Technologies, Eggenstein).

Lipofectamin™: N-[2-({2,5bis[-(3-aminopropyl)amino]-1-oxypentyl}amino)ethyl]-N,N-dimethyl-2,3-bis (9-octadecenyloxy)-1-propanaminium trifluoroacetate)/Dioleoyl-phophatidylethanolamine; 3 : 1 (w/w)

One day before transfection 1 x 10^6 cells were seeded in a 60 mm cell culture dish (Greiner, Nuertingen). For transfection 1 - 5 µg (depending on the experimental assay) of recombinant plasmid DNA were resuspended in 200 ml serum free medium. Simultaneously 8-25 µl (depending on the experimental assay) Lipofectamin ™ were diluted in 200 µl serumfree medium. After combining both solutions a 45 min incubation at room temperature followed. The DNA-liposome mixture was filled up to a final volume of 2 ml and supplied to the cells washed with serumfree medium. Thereafter, the cells were incubated for 5 hours at 37°C. Subsequently, 2 ml of fresh medium containing the double concentration of FCS were added. The next day medium was changed.

For establishing of stable packaging cell clones the cells were overlaid with a selection medium 24 hours after transfection. The Zeocin™ resistance gene (*Streptoalloteichus hinductanus* bleomycin gene) was used as a selection marker. The selection was carried out in DMEM Medium supplemented with 525 µg/ml Zeocin™ (phleomycin from *Streptomyces verticillis*; Invitrogen BV, The Netherlands). The cells were added with fresh selection medium twice a week. After about 4 weeks cell foci representing cell clones could be identified. These colonies were removed individually and transferred into a 24 well plate (flat bottom, Nunc, Wiesbaden) in cell culture medium without antibiotic

supplementation. The medium was changed twice a week. When the cells reached a confluence of about 90%, they were expanded into larger cell culture vials.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT:
(A) NAME: Federal Republic of Germany, finally represented by the President of the Paul-Ehrlich-Institute
(B) STREET: Paul-Ehrlich-Str. 51-59
(C) CITY: Langen
(E) COUNTRY: Germany
(F) POSTAL CODE (ZIP): 63225

(ii) TITLE OF INVENTION: CELL-SPECIFIC RETROVIRAL VECTORS WITH ANTIBODY DOMAINS AND METHOD FOR THE PRODUCTION THEREOF FOR SELECTIVE GENE TRANSFER

(iii) NUMBER OF SEQUENCES: 32

(iv) COMPUTER-READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPA)

(v) PRIOR APPLICATION DATA:
APPLICATION NUMBER: DE 197 52 854.6
DATE OF APPLICATION: 28-11-1997

(2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 4776 Base pairs
(B) TYPE: Nucleotide
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

GAATTCCCGT ACGAGCCATA GATAAAATAA AAGATTTTAT TTAGTCTCCA GAAAAAGGGG 60

GGAATGAAAG ACCCCACCTG TAGGTTTGGC AAGCTAGCTT AAGTAACGCC ATTTTGCAAG 120

GCATGGAAAA ATACATAACT GAGAATAGAG AAGTTCAGAT CAAGGTCAGG AACAGATGGA 180

ACAGCTGAAT ATGGGCCAAA CAGGATATCT GTGGTAAGCA GTTCCTGCCC CGGCTCAGGG 240

CCAAGAACAG ATGGAACAGC TGAATATGGG CCAAACAGGA TATCTGTGGT AAGCAGTTCC 300

TGCCCCGGCT CAGGGCCAAG AACAGATGGT CCCCAGATGC GGTCCAGCCC TCAGCAGTTT 360

CTAGAGAACC ATCAGATGTT TCCAGGGTGC CCCAAGGACC TGAAATGACC CTGTGCCTTA 420

TTTGAACTAA CCAATCAGTT CGCTTCTCGC TTCTGTTCGC GCGCTTCTGC TCCCCGAGCT 480

CAATAAAAGA GCCCACAACC CCTCACTCGG GGCGCCAGTC CTCCGATTGA CTGAGTCGCC 540

CGGGTGGGGG AGCTCGCTGT TGGGCTCGCG GTTGAGGACA AACTCTTCGC GGTCTTTCCA 600

GTACTCTTGG ATCGGAAACC CGTCGGCCTC CGAACGGTAC TCCGCCACCG AGGGACCTGA 660

GCGAGTCCGC ATCGACCGGA TCGGAAAACC TCTCGAGAAA GGCGTCTAAC CAGTCACAGT 720

CGCAAGGTAG GCTGAGCACC GTGGCCGGGC GGCACGGGTG GCGGTCGGGG TTGTTTCTGG 780

CGGAGGTGCT GCTGATGATG TAATTAAGTA GGCGGTCTTG AGACGGCGAT GGTCGAGGTG 840

AGGTGTGGCA GGCTTGAGAT CTGGCCATAC ACTTGAGTGA CAATGACATC CACTTTGCCT 900

TTCTCTCCAC AGGTGTCCAC TCCCAGGTCC AACCGGATCC GAGCTCCACC GCGGTAAAGG 960

TCGCTGGGAA GACCCCGTGG ATCCACCACT CTCGACTCAA GAAAGCTCCT GACAACCAAG 1020

AAGAATGGAC TGTCTCACCA ACCTCCGATC CGCTGAGGGT AAAGTTGACC AGGCGAGCAA 1080

AATCCTAATT CTCCTTGTGG CTTGGTGGGG GTTTGGGACC ACTGCCGAAG TTTCGACTGC 1140

CGGCTCCGGG GGCGGTGGTT CTGGTGGTGG TTCTGGTGGT GGTGGTTCTG GTGGTGGTGG 1200

TTCTGGCGCC AGCCCAGTCC AGTTTATCCC CCTGCTTGTG GGTCTAGGGA TTTCAGGGGC 1260

TACACTTGCT GGTGGAACGG GGCTTGGGGT CTCCGTTCAC ACTTATCACA AGCTCTCTAA 1320

TCAATTGATT GAAGATGTCC AGGCTCTTTC AGGGACCATC AATGACCTAC AGGACCAGAT 1380

TGACTCCCTG GCTGAGGTTG TCTTACAAAA TAGAAGAGGG TTAGACCTAT TGACTGCCGA 1440

ACAAGGAGGA ATATGTCTCG CACTCCAGGA GAAGTGTTGT TTTTACGCTA ACAAGTCGGG 1500

TATCGTACGT GACAAGATCC GAAAACTCCA AGAGGACCTT ATCGAGAGAA AACGTGCACT 1560

GTACGACAAC CCCCTGTGGA GCGGCTTGAA CGGCTTCCTT CCATATTTGC TACCCTTGTT 1620

AGGCCCCCTG TTTGGGCTCA TATTGTTCCT GACCCTCGGC CCGTGCATTA TGAAGACCCT 1680

GACTCGCATT ATACATGACA AAATTCAGGC AGTAAAATCC TAGCACTAGT CCCACAGTAC 1740

AAGCCACTCC CAACAGAGAT GGATACCCTA GGGGTCCGAT GGTCTAAGAA TTCTCGAGTC 1800

TAAGATCGAT CGAATTCCTA GGTCAATGAT TTGACCAGAA TGTACAAGAG CAGTGGGGAA 1860

TGTGGGAGGG GCTTACGAAG GCCTTAAGTG ACTAGGTACC CGATCCAGAC ATGATAAGAT 1920

ACATTGATGA GTTTGGACAA ACCACAACTA GAATGCAGTG AAAAAAATGC TTTATTTGTG 1980

AAATTTGTGA TGCTATTGCT TTATTTGTAA CCATTATAAG CTGCAATAAA CAAGTTAACA 2040

ACAACAATTG CATTCATTTT ATGTTTCAGG TTCAGGGGGA GGTGTGGGAG GTTTTTTAAA 2100

GCAAGTAAAA CCTCTACAAA TCAAGCTGGG CAAGCTAGAT CTAGCTTGGC GTAATCATGG 2160

TCATAGCTGT TTCCTGTGTG AAATTGTTAT CCGCTCACAA TTCCACACAA CATACGAGCC 2220

GGAAGCATAA AGTGTAAAGC CTGGGGTGCC TAATGAGTGA GCTAACTCAC ATTAATTGCG 2280

TTGCGCTCAC TGCCCGCTTT CCAGTCGGGA AACCTGTCGT GCCAGCTGCA TTAATGAATC 2340

GGCCAACGCG CGGGGAGAGG CGGTTTGCGT ATTGGGCGCT CTTCCGCTTC CTCGCTCACT 2400

GACTCGCTGC GCTCGGTCGT TCGGCTGCGG CGAGCGGTAT CAGCTCACTC AAAGGCGGTA 2460

ATACGGTTAT CCACAGAATC AGGGGATAAC GCAGGAAAGA ACATGTGAGC AAAAGGCCAG 2520

CAAAAGGCCA GGAACCGTAA AAAGGCCGCG TTGCTGGCGT TTTTCCATAG GCTCCGCCCC 2580

CCTGACGAGC ATCACAAAAA TCGACGCTCA AGTCAGAGGT GGCGAAACCC GACAGGACTA 2640

TAAAGATACC AGGCGTTTCC CCCTGGAAGC TCCCTCGTGC GCTCTCCTGT TCCGACCCTG 2700

CCGCTTACCG GATACCTGTC CGCCTTTCTC CCTTCGGGAA GCGTGGCGCT TTCTCAATGC 2760

TCACGCTGTA GGTATCTCAG TTCGGTGTAG GTCGTTCGCT CCAAGCTGGG CTGTGTGCAC 2820

GAACCCCCCG TTCAGCCCGA CCGCTGCGCC TTATCCGGTA ACTATCGTCT TGAGTCCAAC 2880

CCGGTAAGAC ACGACTTATC GCCACTGGCA GCAGCCACTG GTAACAGGAT TAGCAGAGCG 2940

AGGTATGTAG GCGGTGCTAC AGAGTTCTTG AAGTGGTGGC CTAACTACGG CTACACTAGA 3000

AGGACAGTAT TTGGTATCTG CGCTCTGCTG AAGCCAGTTA CCTTCGGAAA AAGAGTTGGT 3060

AGCTCTTGAT CCGGCAAACA AACCACCGCT GGTAGCGGTG GTTTTTTTGT TTGCAAGCAG 3120

CAGATTACGC GCAGAAAAAA AGGATCTCAA GAAGATCCTT TGATCTTTTC TACGGGGTCT 3180

GACGCTCAGT GGAACGAAAA CTCACGTTAA GGGATTTTGG TCATGAGATT ATCAAAAAGG 3240

ATCTTCACCT AGATCCTTTT AAATTAAAAA TGAAGTTTTA AATCAATCTA AAGTATATAT 3300

GAGTAAACTT GGTCTGACAG TTACCAATGC TTAATCAGTG AGGCACCTAT CTCAGCGATC 3360

TGTCTATTTC GTTCATCCAT AGTTGCCTGA CTCCCCGTCG TGTAGATAAC TACGATACGG 3420

GAGGGCTTAC CATCTGGCCC CAGTGCTGCA ATGATACCGC GAGACCCACG CTCACCGGCT 3480

CCAGATTTAT CAGCAATAAA CCAGCCAGCC GGAAGGGCCG AGCGCAGAAG TGGTCCTGCA 3540

ACTTTATCCG CCTCCATCCA GTCTATTAAT TGTTGCCGGG AAGCTAGAGT AAGTAGTTCG 3600

CCAGTTAATA GTTTGCGCAA CGTTGTTGCC ATTGCTACAG GCATCGTGGT GTCACGCTCG 3660

TCGTTTGGTA TGGCTTCATT CAGCTCCGGT TCCCAACGAT CAAGGCGAGT TACATGATCC 3720

CCCATGTTGT GCAAAAAAGC GGTTAGCTCC TTCGGTCCTC CGATCGTTGT CAGAAGTAAG 3780

TTGGCCGCAG TGTTATCACT CATGGTTATG GCAGCACTGC ATAATTCTCT TACTGTCATG 3840

CCATCCGTAA GATGCTTTTC TGTGACTGGT GAGTACTCAA CCAAGTCATT CTGAGAATAG 3900

TGTATGCGGC GACCGAGTTG CTCTTGCCCG GCGTCAATAC GGGATAATAC CGCGCCACAT 3960

AGCAGAACTT TAAAAGTGCT CATCATTGGA AAACGTTCTT CGGGGCGAAA ACTCTCAAGG 4020

ATCTTACCGC TGTTGAGATC CAGTTCGATG TAACCCACTC GTGCACCCAA CTGATCTTCA 4080

GCATCTTTTA CTTTCACCAG CGTTTCTGGG TGAGCAAAAA CAGGAAGGCA AAATGCCGCA 4140

AAAAAGGGAA TAAGGGCGAC ACGGAAATGT TGAATACTCA TACTCTTCCT TTTTCAATAT 4200

TATTGAAGCA TTTATCAGGG TTATTGTCTC ATGAGCGGAT ACATATTTGA ATGTATTTAG 4260

AAAAATAAAC AAATAGGGGT TCCGCGCACA TTTCCCCGAA AAGTGCCACC TGACGTCTAA 4320

GAAACCATTA TTATCATGAC ATTAACCTAT AAAAATAGGC GTATCACGAG GCCCTTTCGT 4380

CTCGCGCGTT TCGGTGATGA CGGTGAAAAC CTCTGACACA TGCAGCTCCC GGAGACGGTC 4440

ACAGCTTGTC TGTAAGCGGA TGCCGGGAGC AGACAAGCCC GTCAGGGCGC GTCAGCGGGT 4500

GTTGGCGGGT GTCGGGGCTG GCTTAACTAT GCGGCATCAG AGCAGATTGT ACTGAGAGTG 4560

CACCATATGC GGTGTGAAAT ACCGCACAGA TGCGTAAGGA GAAAATACCG CATCAGGCGC 4620

CATTCGCCAT TCAGGCTGCG CAACTGTTGG GAAGGGCGAT CGGTGCGGGC CTCTTCGCTA 4680

TTACGCCAGC TGGCGAAAGG GGGATGTGCT GCAAGGCGAT TAAGTTGGGT AACGCCAGGG 4740

TTTTCCCAGT CACGACGTTG TAAAACGACG GCCAGT 4776

(2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 Amino acids
(B) TYPE: Amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: Protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

Met Lys Asp Pro Thr Cys Arg Phe Gly Lys Leu Ala
5 10

(2) INFORMATION FOR SEQ ID NO: 3:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 Amino acids
(B) TYPE: Amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: Protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

Met Glu Lys Tyr Ile Thr Glu Asn Arg Glu Val Gln Ile Lys Val Arg
5 10 15

Asn Arg Trp Asn Ser
20

(2) INFORMATION FOR SEQ ID NO: 4:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 8 Amino acids
(B) TYPE: Amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: Protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

Met Gly Gln Thr Gly Tyr Leu Trp
5

(2) INFORMATION FOR SEQ ID NO: 5:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 Amino acids
(B) TYPE: Amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: Protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

Met Glu Gln Leu Asn Met Gly Gln Thr Gly Tyr Leu Trp
5 10

(2) INFORMATION FOR SEQ ID NO: 6:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 Amino acids
(B) TYPE: Amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: Protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

Met Val Pro Arg Cys Gly Pro Ala Leu Ser Ser Phe

```
                  5                        10
```

(2) INFORMATION FOR SEQ ID NO: 7:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 Amino acids
(B) TYPE: Amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: Protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

```
Met Phe Pro Gly Cys Pro Lys Asp Leu Lys
                5                   10
```

(2) INFORMATION FOR SEQ ID NO: 8:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 Amino acids
(B) TYPE: Amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: Protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

```
Met Val Glu Val Arg Cys Gly Arg Leu Glu Ile Trp Pro Tyr Thr
                5                   10                  15
```

(2) INFORMATION FOR SEQ ID NO: 9:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 Amino acids
(B) TYPE: Amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: Protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

```
Met Thr Ser Thr Leu Pro Phe Ser Pro Gln Val Ser Thr Pro Arg Ser
                5                   10                  15
Asn Arg Ile Arg Ala Pro Pro Arg
            20
```

(2) INFORMATION FOR SEQ ID NO: 10:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 232 Amino acids
(B) TYPE: Amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: Protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

```
Met Asp Cys Leu Thr Asn Leu Arg Ser Ala Glu Gly Lys Val Asp Gln
                5                   10                  15
Ala Ser Lys Ile Leu Ile Leu Leu Val Ala Trp Trp Gly Phe Gly Thr
            20                  25                  30
Thr Ala Glu Val Ser Thr Ala Gly Ser Gly Gly Gly Gly Ser Gly Gly
        35                  40                  45
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Ala Ser Pro
    50                  55                  60
Val Gln Phe Ile Pro Leu Leu Val Gly Leu Gly Ile Ser Gly Ala Thr
65                  70                  75                  80
Leu Ala Gly Gly Thr Gly Leu Gly Val Ser Val His Thr Tyr His Lys
                85                  90                  95
Leu Ser Asn Gln Leu Ile Glu Asp Val Gln Ala Leu Ser Gly Thr Ile
            100                 105                 110
Asn Asp Leu Gln Asp Gln Ile Asp Ser Leu Ala Glu Val Val Leu Gln
        115                 120                 125
Asn Arg Arg Gly Leu Asp Leu Leu Thr Ala Glu Gln Gly Gly Ile Cys
130                 135                 140
Leu Ala Leu Gln Glu Lys Cys Cys Phe Tyr Ala Asn Lys Ser Gly Ile
145                 150                 155                 160
Val Arg Asp Lys Ile Arg Lys Leu Gln Glu Asp Leu Ile Glu Arg Lys
                165                 170                 175
```

Arg Ala Leu Tyr Asp Asn Pro Leu Trp Ser Gly Leu Asn Gly Phe Leu
180 185 190
Pro Tyr Leu Leu Pro Leu Leu Gly Pro Leu Phe Gly Leu Ile Leu Phe
195 200 205
Leu Thr Leu Gly Pro Cys Ile Met Lys Thr Leu Thr Arg Ile Ile His
210 215 220
Asp Lys Ile Gln Ala Val Lys Ser
225 230

(2) INFORMATION FOR SEQ ID NO: 11:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 Amino acids
(B) TYPE: Amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: Protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:
Met Asp Thr Leu Gly Val Arg Trp Ser Lys Asn Ser Arg Val
5 10

(2) INFORMATION FOR SEQ ID NO: 12:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 Amino acids
(B) TYPE: Amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: Protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:
Met Tyr Lys Ser Ser Gly Glu Cys Gly Arg Gly Leu Arg Arg Pro
5 10 15

(2) INFORMATION FOR SEQ ID NO: 13:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16 Amino acids
(B) TYPE: Amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: Protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:
Met Ile Arg Tyr Ile Asp Glu Phe Gly Gln Thr Thr Thr Arg Met Gln
5 10 15

(2) INFORMATION FOR SEQ ID NO:14:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 4 Amino acids
(B) TYPE: Amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: Protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:

Met Leu Tyr Leu

(2) INFORMATION FOR SEQ ID NO: 15:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 Amino acids
(B) TYPE: Amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: Protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:

Met Leu Leu Leu Tyr Leu
5

(2) INFORMATION FOR SEQ ID NO: 16:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 Amino acids
(B) TYPE: Amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:

Met Phe Gln Val Gln Gly Glu Val Trp Glu Val Phe
5 10

(2) INFORMATION FOR SEQ ID NO: 17:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 Amino acids
(B) TYPE: Amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: Protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17:

Met Val Ile Ala Val Ser Cys Val Lys Leu Leu Ser Ala His Asn Ser
5 10 15
Thr Gln His Thr Ser Arg Lys His Lys Val
20 25

(2) INFORMATION FOR SEQ ID NO: 18:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 49 Amino acids
(B) TYPE: Amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: Protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18:

Met Ser Glu Leu Thr His Ile Asn Cys Val Ala Leu Thr Ala Arg Phe
5 10 15
Pro Val Gly Lys Pro Val Val Pro Ala Ala Leu Met Asn Arg Pro Thr
20 25 30
Arg Gly Glu Arg Arg Phe Ala Tyr Trp Ala Leu Phe Arg Phe Leu Ala
35 40 45
His

(2) INFORMATION FOR SEQ ID NO: 19:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 4 Amino acids
(B) TYPE: Amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: Protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19:

Met Leu Thr Leu

(2) INFORMATION FOR SEQ ID NO: 20:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 Amino acids
(B) TYPE: Amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: Protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20:

Met Arg Leu Ser Lys Arg Ile Phe Thr
5

(2) INFORMATION FOR SEQ ID NO: 21:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 Amino acids
(B) TYPE: Amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: Protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22:

Met Ser Lys Leu Gly Leu Thr Val Thr Asn Ala
5 10

(2) INFORMATION FOR SEQ ID NO: 23:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 88 Amino acids
(B) TYPE: Amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: Protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23:

```
Met Ile Pro Arg Asp Pro Arg Ser Pro Ala Pro Asp Leu Ser Ala Ile
                5                   10                  15
Asn Gln Pro Ala Gly Arg Ala Glu Arg Arg Ser Gly Pro Ala Thr Leu
            20                  25                  30
Ser Ala Ser Ile Gln Ser Ile Asn Cys Cys Arg Glu Ala Arg Val Ser
        35                  40                  45
Ser Ser Pro Val Asn Ser Leu Arg Asn Val Val Ala Ile Ala Thr Gly
    50                  55                  60
Ile Val Val Ser Arg Ser Ser Phe Gly Met Ala Ser Phe Ser Ser Gly
65                  70                  75                  80
Ser Gln Arg Ser Arg Arg Val Thr
                85
```

(2) INFORMATION FOR SEQ ID NO: 24:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 56 Amino acids
(B) TYPE: Amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: Protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24:

```
Met Leu Cys Lys Lys Ala Val Ser Ser Phe Gly Pro Pro Ile Val Val
                5                   10                  15
Arg Ser Lys Leu Ala Ala Val Leu Ser Leu Met Val Met Ala Ala Leu
            20                  25                  30
His Asn Ser Leu Thr Val Met Pro Ser Val Arg Cys Phe Ser Val Thr
        35                  40                  45
Gly Glu Tyr Ser Thr Lys Ser Phe
    50                  55
```

(2) INFORMATION FOR SEQ ID NO: 25:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 49 Amino acids
(B) TYPE: Amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: Protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25:

```
Met Arg Arg Pro Ser Cys Ser Cys Pro Ala Ser Ile Arg Asp Asn Thr
                5                   10                  15
Ala Pro His Ser Arg Thr Leu Lys Val Leu Ile Ile Gly Lys Arg Ser
            20                  25                  30
Ser Gly Arg Lys Leu Ser Arg Ile Leu Pro Leu Leu Arg Ser Ser Ser
        35                  40                  45
Met
```

(2) INFORMATION FOR SEQ ID NO: 26:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 Amino acids
(B) TYPE: Amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: Protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26:

```
Met Pro Gln Lys Arg Glu
                5
```

(2) INFORMATION FOR SEQ ID NO: 27:
(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 27 Amino acids
(B) TYPE: Amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: Protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 27:

```
Met Leu Asn Thr His Thr Leu Pro Phe Ser Ile Leu Leu Lys His Leu
                5                   10                  15
Ser Gly Leu Leu Ser His Glu Arg Ile His Ile
            20                  25
```

(2) INFORMATION FOR SEQ ID NO: 28:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 5 Amino acids
(B) TYPE: Amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: Protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 28:

```
Met Tyr Leu Glu Lys
                5
```

(2) INFORMATION FOR SEQ ID NO: 29:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 Amino acids
(B) TYPE: Amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: Protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 29:

```
Met Thr Leu Thr Tyr Lys Asn Arg Arg Ile Thr Arg Pro Phe Arg Leu
                5                   10                  15
Ala Arg Phe Gly Asp Asp Gly Glu Asn Leu
            20                  25
```

(2) INFORMATION FOR SEQ ID NO: 30:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 Amino acids
(B) TYPE: Amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: Protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 30:

```
Met Gln Leu Pro Glu Thr Val Thr Ala Cys Leu
                5                   10
```

(2) INFORMATION FOR SEQ ID NO: 31:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 31 Amino acids
(B) TYPE: Amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: Protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 31:

```
Met Pro Gly Ala Asp Lys Pro Val Arg Ala Arg Gln Arg Val Leu Ala
                5                   10                  15
Gly Val Gly Ala Gly Leu Thr Met Arg His Gln Ser Arg Leu Tyr
            20                  25                  30
```

(2) INFORMATION FOR SEQ ID NO:32:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 65 Amino acids
(B) TYPE: Amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 32:

```
Met Arg Cys Glu Ile Pro His Arg Cys Val Arg Arg Lys Tyr Arg Ile
                 5                  10                  15
Arg Arg His Ser Pro Phe Arg Leu Arg Asn Cys Trp Glu Gly Arg Ser
            20                  25                  30
Val Arg Ala Ser Ser Leu Leu Arg Gln Leu Ala Lys Gly Gly Cys Ala
        35                  40                  45
Ala Arg Arg Leu Ser Trp Val Thr Pro Gly Phe Ser Gln Ser Arg Arg
    45                  50                  55
Cys Lys Thr Thr Ala Ser
60                  65
```

CLAIMS

1. A method for the production of cell-specific retroviral vectors comprising the following steps:

a) immunizing a mammal with one or more cell population(s),

b) isolating RNA from the immunized mammal, comprising the B cell RNA,

c) production of cDNA regions of the variable regions of the immunoglobulin heavy and light chain from the isolated RNA by means of RT-PCR with primers for the immunoglobulin heavy and light chain wherein the primers comprise the nucleic acid sequence for an oligopeptid linker,

d) ligation of the cDNA regions to scFv-cDNAs,

e) ligation of the scFv-cDNAs into a phagemid-vector and transformation of a host bacterium with the phagemid vector,

f) isolation of phages binding to the cell population(s) used in step a) by means of selection,

g) isolation of cell-specific phages from the phages obtained in step f) which only bind to the cell population(s) used in step a) by means of selection,

h) excision of the scFv-encoding DNA fragments from the cell-specific phages obtained in step g) and ligation into a psi-negative retroviral Env expression vector,

i) transformation of the resulting Env-scFv expression vector into a packaging cell, and

j) isolation of the retroviral vectors secreted by the packaging cell.

2. The method according to claim 1 wherein the cell-specific phages obtained in step g) are isolated.

3. The method according to claim 1 or 2 wherein the steps f) and/or g) are repeated at least once.

4. The method according to any of the claims 1 to 3 further comprising the step of:

k) isolating the retroviral vectors secreted by the packaging cell, which transduce the cells of the cell population(s) by means of selection.

5. The method according to any of the claims 1 to 4 wherein the mammal is selected from the group consisting of mouse, rat, guinea pig, rabbit, goat or sheep.

6. The method according to any of the claims 1 to 4 wherein the cell population(s) is/are selected from the group consisting of man, mouse, rat, sheep, cattle or pig.

7. The method according to claim 6 wherein the cell population(s) is/are selected from the group comprising T cells, epithelial cells, muscle cells, hematopoietic cells, stem cells, neural cells, carcinoma cells or liver cells.

8. The method according to any of the claims 1 to 7 wherein the env gene of the psi-negative retroviral Env expression vector is derived from spleen necrosis virus (SNV).

9. The method according to claim 8 wherein the expression vector is the vector having the designation pTC53.

10. Retroviral vectors, obtainable by the method according to any of the claims 1 to 9.

11. The use of the retroviral vectors according to claim 10 as medicament.

12. The use of the vector according to claim 10 for the preparation of a medicament for somatic gene therapy, vaccination therapy or diagnostics.

13. The use of the vector according to claim 10 for the preparation of a medicament for the therapy of cystic fibrosis, ADA deficiency, chronic granulomatosis or HIV-1 infection.

14. Retroviral packaging cell for obtaining the retroviral vectors according to claim 10 transformed with one or more psi-negative expression construct(s) expressing gag, pol and/or env gene products as well as with a psi-negative Env-scFv expression construct according to claim 1h).

15. Retroviral packaging cell according to claim 14 further comprising a psi-positive expression construct comprising a nucleic acid fragment which has to be introduced into the cell to be transduced by the retroviral vector.

16. Retroviral packaging cell according to claim 15 wherein the nucleic acid fragment comprises a therapeutic gene or its DNA fragment and/or a reporter gene or a resistance gene.

17. Retroviral packaging cell according to claim 16 wherein the therapeutic gene or its nucleic acid fragment comprises the CFTR, phox91, ADA, IL-16, p53 or revM10 gene or one or more vaccination gene(s), e.g. recombinant gp120 and IL-16.

18. Retroviral packaging cell according to claim 16, wherein the reporter gene comprises β-galactosidase, "Green Fluorescent Protein", luciferase and the resistance gene neomycin.

Abstract

The invention relates to cell-specific retroviral vectors with antibody recognition domains (scFv), which are suitable for cell-specific transduction of a selected mammal cell type (cell targeting), to methods for the production of the cell-specific retroviral vectors and to the use thereof in gene transfers into selected cells. The invention further relates to retroviral packaging cells to obtain cell-specific retroviral vectors according to the present invention.

Fig. 1

Fig. 2

09/555350



Fig. 3



Fig. 4A



Fig. 4B

Attorney's Docket No.: 11692-004001
Client's Ref. No.: 158-2US

COMBINED DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled CELL-SPECIFIC RETROVIRAL VECTORS WITH ANTIBODY DOMAINS AND METHOD FOR THE PRODUCTION THEREOF FOR SELECTIVE GENE TRANSFER, the specification of which was filed on May 26, 2000 as Application Serial No. 09/555,350.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose all information I know to be material to patentability in accordance with Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

Country	Application No.	Filing Date	Priority Claimed
Germany	197 25 854.6	November 28, 1997	[X] Yes [ ] No
PCT	PCT/DE98/03543	November 27, 1998	[X] Yes [ ] No

I hereby appoint the following attorneys and/or agents to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

J. Peter Fasse, Reg. No. 32,983
Anita L. Meiklejohn, Reg. No. 35,283
Lee Crews, Reg. No. 43,567
John W. Freeman, Reg. No. 29,066
Timothy A. French, Reg. No. 30,175
John F. Hayden, Reg. No. 37,640

Address all telephone calls to J. PETER FASSE at telephone number (617) 542-5070.

Address all correspondence to J. PETER FASSE at:

FISH & RICHARDSON P.C.
225 Franklin Street
Boston, MA 02110-2804

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patents issued thereon.

2.

Attorney's Docket No.: 11692-004001
Client's Ref. No.: 158-2US

Combined Declaration and Power of Attorney

1-00.

Full Name of Inventor: KLAUS CICHUTEK

Inventor's Signature: _____ DEX Date: August 16, 2000

Residence Address: Theodor-Heuss-Str. 54, D-63225 Langen, Germany

Citizenship: German

Post Office Address: Same As Above

2-00

Full Name of Inventor: MARTIN ENGELSTADTER

Inventor's Signature: _____ DEX Date: August 16, 2000

Residence Address: Gebrüder-Grimm-Str. 33, D-63322 Roedermark, Germany

Citizenship: German

Post Office Address: Same As Above